How Acetazolamide Helps Correct Metabolic Alkalosis in ICU Patients
Author Information
Author(s): Miriam Moviat, Peter Pickkers, Peter HJ van der Voort, Johannes G van der Hoeven
Primary Institution: Radboud University Nijmegen Medical Centre
Hypothesis
Acetazolamide, by inhibiting carbonic anhydrase in the proximal tubules, causes excretion of strong cations and retention of chloride, decreasing the serum strong ion difference (SID).
Conclusion
A single dose of acetazolamide effectively corrects metabolic alkalosis in critically ill patients by decreasing the serum SID.
Supporting Evidence
- Acetazolamide administration led to a significant decrease in serum pH from 7.49 to 7.46.
- Serum strong ion difference decreased significantly from 41.5 to 38.0 mEq/l.
- Increased urinary excretion of sodium without chloride was observed after acetazolamide administration.
Takeaway
Acetazolamide is a medicine that helps fix a problem called metabolic alkalosis by changing the balance of certain chemicals in the blood.
Methodology
Fifteen ICU patients with metabolic alkalosis were treated with 500 mg acetazolamide, and various blood and urine parameters were measured over 72 hours.
Potential Biases
Potential bias due to the lack of informed consent and the observational nature of the study.
Limitations
The study was limited to a small sample size and specific patient criteria, which may not generalize to all patients with metabolic alkalosis.
Participant Demographics
Patients were predominantly older adults, with 87% mechanically ventilated and 47% treated with diuretics.
Statistical Information
P-Value
P = 0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website